Back

Estimating composite benefits of combination medical therapy in heart failure with mildly reduced and preserved ejection fraction

23 May 2022 (11:07 - 11:15)
Organised by:
Congress Presentation Part of: Imaging in chronic heart failure Heart Failure with Mid-Range Ejection Fraction (HFmrEF) HFA Premium Access Heart Failure 2022

About the speaker

Photo
Doctor Muthiah Vaduganathan

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

6 More presentations in this session

Presentation thumbnail
Left atrial strain has superior prognostic value to ventricular function and delayed-enhancement in dilated cardiomyopathy, a long-term cardiac magnetic resonance study.
Miss A. Raafs (Eindhoven, NL)
Abstract Slides Video
Presentation thumbnail
Cardiac magnetic resonance T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy
Doctor D. Lavall (Leipzig, DE)
Abstract Slides Video
Presentation thumbnail
Prognostic value of left ventricular global longitudinal strain in post-STEMI patients with severe functional mitral regurgitation
Presentation thumbnail
The impact of ventricular-arterial coupling derived from proximal aortic stiffness on aerobic capacity across the heart failure spectrum.
Doctor N. Pugliese (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Right ventricular dyssynchrony in patients with HFrEF: combined gated blood-pool SPECT and invasive hemodynamic study
Doctor L. Monzo (Vandoeuvre-Les-Nancy, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Imaging in chronic heart failure
Video

The Event

Event poster

Heart Failure 2022

23 May 2022 11:07 CET
You may be interested in
thumbnail
Congress Presentation
Lifetime Benefits of Combination Therapy in HFpEF
31 August 2025
thumbnail
Congress Presentation
Should the treatment of HFrEF and HFmrEF be the same?
28 August 2023
thumbnail
Congress Presentation
Chronic heart failure.
24 May 2022
thumbnail
Congress Presentation
Do we need trials of combination pharmacotherapy?
24 May 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources